Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 163 of 6351
-
Immunotherapy shows promise as First-Line attack on tough lung cancer
Disease control OngoingThis is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lympho…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged cord blood transplant shows promise in blood cancer trial
Disease control CompletedThis study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, m…
Phase 3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Brain cancer breakthrough? trial adds radiation during surgery to fight glioblastoma
Disease control OngoingINTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radi…
Phase 3 • Sponsor: Universitätsmedizin Mannheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New pill combo shows promise in slowing advanced breast cancer
Disease control OngoingThe main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Electric field therapy extends life in advanced lung cancer trial
Disease control CompletedThe study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment. The…
Phase 3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New stem cell approach could fix immune systems in kids
Disease control OngoingThis is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with alpha/beta T and CD19+ depleted peripheral stem cell grafts from unrelated or partially matched related donors. There are two conditioning regimens d…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise for advanced prostate cancer
Disease control CompletedThe purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can radiation turn tumors into targets for immunotherapy?
Disease control CompletedAlthough it is usually described as an immunosuppressive modality and not thought of as immunotherapy, there are new preclinical evidences suggesting that high-dose ionizing irradiation (IR) results in direct tumour cell death and augments tumour-specific immunity, which enhances…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Promising combo therapy aims to beat B-ALL without transplant
Disease control Recruiting nowThis phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the bod…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Genetic roadmap guides new hope for tough leukemia
Disease control Recruiting nowThis screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study…
Phase 2/3 • Sponsor: Beat AML, LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
HIV patients may ditch daily pills for monthly shots
Disease control OngoingThe First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppress…
Phase 3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug cocktails show promise in slowing advanced kidney cancer
Disease control OngoingThe primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Ev…
Phase 3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Womb transplants offer hope for women unable to carry a pregnancy
Disease control By invitation onlyTransplantation of an uterus
Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Can a targeted pill boost Chemotherapy's punch against lymphoma?
Disease control OngoingPhase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients : DLBCL : taze…
Phase 1/2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drugs aim to keep boys with duchenne walking longer
Disease control CompletedThe main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
Phase 3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
French study aims to perfect leukemia treatment for kids
Disease control OngoingA still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase). It is known that administering ASNase res…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 18:21 UTC
-
Could shedding pounds after breast cancer keep the disease away?
Disease control OngoingThis randomized phase III trial compares whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Immunotherapy combo boosts survival in advanced kidney cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC). The primary hypotheses of this s…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for rare blood disorder: Half-Matched transplants show promise
Disease control Recruiting nowSevere aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of surviva…
Phase 2 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can a single ketamine infusion quiet the obsessive mind?
Disease control CompletedThe purpose of this study is to understand how ketamine brings about rapid improvement in Obsessive-Compulsive Disorder (OCD) symptoms.
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC